- H92 -

About us Our work Support us NewsResources Contact About us About us Our work NewsResources Contact About us New medicines for lasting change Were tackling the worlds most challenging diseases so that communities can thrive around the world About us Our work NewsResources Contact About us FEATURED Ghana rolls out moxidectin a new treatment for river blindness FEATURED Ghana becomes first river blindnessendemic country to approve moxidectin About us Our work NewsResources Contact About us FEATURED 2022 2023 Annual Report Our 202223 Annual Report documents our medicine development progress highlights our achievements over the year and presents our approach to looking forward and continuing our global presence. WHATWEDO We develop new and improved medicines for neglected diseases Medicines Development for Global Health MDGH develops new medicines for people and communities who are disadvantaged by the traditional consideration of market returns. In 2018 we became the first solo notforprofit company to achieve FDA approval for a novel medicine when we registered moxidectin the first new treatment for river blindness onchocerciasis in 20 years. Supported by our collaborators we are working towards making a lasting change in the lives of people affected by neglected diseases.